COST-EFFECTIVENESS OF COMPLYING WITH TREATMENT GUIDELINES IN SWEDEN

被引：0
|
作者：
Jonsson, E. [1 ]
Hansson-Hedblom, A. [1 ]
Ljunggren, O. [2 ]
Akesson, K. [3 ]
Spangeus, A. [4 ]
Borgstrom, F. [1 ,5 ]
Kanis, J. A. [6 ,7 ]
机构：
[1] Quantify Res, Stockholm, Sweden
[2] Uppsala Univ, Dept Med Sci Endocrinol & Mineral Metab, Uppsala, Sweden
[3] Lund Univ, Dept Clin Sci, Clin & Mol Osteoporosis Unit, Malmo, Sweden
[4] Linkoping Univ, Dept Med & Hlth Sci, Linkoping, Sweden
[5] Karolinska Inst, Stockholm, Sweden
[6] Catholic Univ Australian, Melbourne, Vic, Australia
[7] Univ Sheffield, Sheffield, S Yorkshire, England
来源：
OSTEOPOROSIS INTERNATIONAL | 2017年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P747
引用
收藏
页码：S440 / S440
页数：1
相关论文
共 50 条
  • [31] The cost-effectiveness of oral triptan therapy in Sweden
    Ramsberg, J.
    Henriksson, M.
    CEPHALALGIA, 2007, 27 (01) : 54 - 62
  • [32] Cost-Effectiveness of Erenumab for the Preventive Treatment of Migraine in Patients with Prior Treatment Failures in Sweden
    Mahon, Ronan
    Lang, Andrea
    Vo, Pamela
    Huels, Jasper
    Cooney, Philip
    Danyliv, Andriy
    Vudumula, Umakanth
    Vadapalle, Sreelatha
    Maniyar, Farooq
    Goadsby, Peter J.
    PHARMACOECONOMICS, 2021, 39 (03) : 357 - 372
  • [33] The cost-effectiveness of hypertension treatment in Sweden: An analysis of the criteria for intervention and the choice of drug treatment
    Johannesson, M
    JOURNAL OF HUMAN HYPERTENSION, 1996, 10 : S23 - S26
  • [34] Cost-Effectiveness of Erenumab for the Preventive Treatment of Migraine in Patients with Prior Treatment Failures in Sweden
    Ronan Mahon
    Andrea Lang
    Pamela Vo
    Jasper Huels
    Philip Cooney
    Andriy Danyliv
    Umakanth Vudumula
    Sreelatha Vadapalle
    Farooq Maniyar
    Peter J. Goadsby
    PharmacoEconomics, 2021, 39 : 357 - 372
  • [35] Cost and cost-effectiveness guidelines: which ones to use?
    Walker, D
    HEALTH POLICY AND PLANNING, 2001, 16 (01) : 113 - 121
  • [36] Cost-effectiveness of implementing new guidelines for treatment of hypertension in general practice
    Richardson, G
    Godfrey, L
    Gravelle, H
    Watt, I
    BRITISH JOURNAL OF GENERAL PRACTICE, 2004, 54 (507): : 765 - 771
  • [37] Cost-effectiveness analysis of initial HIV treatment under Italian guidelines
    Colombo, Giorgio L.
    Colangeli, Vincenzo
    Di Biagio, Antonio
    Di Matteo, Sergio
    Viscoli, Claudio
    Viale, Pierluigi
    CLINICOECONOMICS AND OUTCOMES RESEARCH, 2011, 3 : 197 - 205
  • [38] The cost-effectiveness of the treatment of high risk women with osteoporosis, hypertension and hyperlipidaemia in Sweden
    Zethraeus, N.
    Strom, O.
    Borgstrom, F.
    Kanis, J. A.
    Jonsson, B.
    OSTEOPOROSIS INTERNATIONAL, 2008, 19 (06) : 819 - 827
  • [39] Economics of a new treatment for diabetic foot ulcers:: The cost-effectiveness of becaplermin in Sweden
    Willis, M
    Persson, U
    Ödegaard, K
    DIABETOLOGIA, 1999, 42 : A309 - A309
  • [40] Cost-effectiveness of licensed treatment options for restless legs syndrome in the UK and Sweden
    Lees, M.
    Roberts, G.
    Tabberer, M.
    DasGupta, R.
    Finnern, H. W.
    CURRENT MEDICAL RESEARCH AND OPINION, 2008, 24 (10) : 2919 - 2930
12345